ERBB2 and breast cancer: We previously found that HER2-amplified BT474 breast cancer persister cells have a broadly disabled antioxidant program with diminished expression of NRF2 target genes including system xC− components and decreased levels of GSH and nicotinamide adenine dinucleotide phosphate (NADPH) (reduced form of NADP+) (3).